Literature DB >> 20408991

Administration of zonisamide in three cases of dementia with Lewy bodies.

Toshinari Odawara1, Kazumasa Shiozaki, Takashi Togo, Yoshio Hirayasu.   

Abstract

Zonisamide (ZNS) add-on administration was used to treat parkinsonian symptoms in three cases of dementia with Lewy bodies (DLB). ZNS was added after doses of the anti-Parkinson's disease drugs were fixed for at least 4 weeks. A total of 25 mg of ZNS produced mild-moderate improvement of parkinsonian symptoms in two cases, but it did not affect the cognitive functions and behavioral or psychological symptoms. Caregiver burdens were decreased in two cases. Although dizziness and drowsiness were detected, these were improved by decreasing the dose. ZNS may be useful for the treatment of motor symptoms in DLB patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20408991     DOI: 10.1111/j.1440-1819.2010.02075.x

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN: 1323-1316            Impact factor:   5.188


  5 in total

Review 1.  Clinical drug development for dementia with Lewy bodies: past and present.

Authors:  Garam Lee; Jeffrey Cummings; Boris Decourt; James B Leverenz; Marwan N Sabbagh
Journal:  Expert Opin Investig Drugs       Date:  2019-10-28       Impact factor: 6.206

Review 2.  The efficacy and safety of newer anticonvulsants in patients with dementia.

Authors:  Christian R Dolder; Kimberly L Nealy
Journal:  Drugs Aging       Date:  2012-08-01       Impact factor: 3.923

Review 3.  The Application of Zonisamide to Patients Suffering from Dementia with Lewy Bodies: Emerging Clinical Data.

Authors:  Babak Tousi; James B Leverenz
Journal:  Drug Des Devel Ther       Date:  2021-05-03       Impact factor: 4.162

4.  Adjunct zonisamide to levodopa for DLB parkinsonism: A randomized double-blind phase 2 study.

Authors:  Miho Murata; Toshinari Odawara; Kazuko Hasegawa; Sayaka Iiyama; Masatoshi Nakamura; Masaaki Tagawa; Kenji Kosaka
Journal:  Neurology       Date:  2018-01-24       Impact factor: 9.910

5.  Efficacy and Safety of Zonisamide in Dementia with Lewy Bodies Patients with Parkinsonism: A Post Hoc Analysis of Two Randomized, Double-Blind, Placebo-Controlled Trials.

Authors:  Kazuko Hasegawa; Kenji Kochi; Hidenori Maruyama; Osamu Konishi; Shunji Toya; Toshinari Odawara
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.